Authors
Monath, Thomas P.Liu, Jian
Kanesa-Thasan, Niranjan
Myers, Gwendolyn A.
Nichols, Richard
Deary, Alison
McCarthy, Karen
Johnson, Casey
Ermak, Thomas
Shin, Sunheang
Arroyo, Juan
Guirakhoo, Farshad
Kennedy, Jeffrey S.
Ennis, Francis A.
Green, Sharone
Bedford, Philip
UMass Chan Affiliations
Department of Medicine, Division of Infectious Diseases and ImmunologyDocument Type
Journal ArticlePublication Date
2006-04-25Keywords
ImmunityImmunology and Infectious Disease
Immunology of Infectious Disease
Infectious Disease
Metadata
Show full item recordAbstract
West Nile (WN) virus is an important cause of febrile exanthem and encephalitis. Since it invaded the U.S. in 1999, > 19,000 human cases have been reported. The threat of continued epidemics has spurred efforts to develop vaccines. ChimeriVax-WN02 is a live, attenuated recombinant vaccine constructed from an infectious clone of yellow fever (YF) 17D virus in which the premembrane and envelope genes of 17D have been replaced by the corresponding genes of WN virus. Preclinical tests in monkeys defined sites of vaccine virus replication in vivo. ChimeriVax-WN02 and YF 17D had similar biodistribution but different multiplication kinetics. Prominent sites of replication were skin and lymphoid tissues, generally sparing vital organs. Viruses were cleared from blood by day 7 and from tissues around day 14. In a clinical study, healthy adults were inoculated with 5.0 log(10) plaque-forming units (PFU) (n = 30) or 3.0 log10 PFU (n = 15) of ChimeriVax-WN02, commercial YF vaccine (YF-VAX, n = 5), or placebo (n = 30). The incidence of adverse events in subjects receiving the vaccine was similar to that in the placebo group. Transient viremia was detected in 42 of 45 (93%) of ChimeriVax-WN02 subjects, and four of five (80%) of YF-VAX subjects. All subjects developed neutralizing antibodies to WN or YF, respectively, and the majority developed specific T cell responses. ChimeriVax-WN02 rapidly elicits strong immune responses after a single dose, and is a promising candidate warranting further evaluation for prevention of WN disease.Source
Proc Natl Acad Sci U S A. 2006 Apr 25;103(17):6694-9. Epub 2006 Apr 14. DOI: 10.1073/pnas.0601932103 Link to article on publisher's siteDOI
10.1073/pnas.0601932103Permanent Link to this Item
http://hdl.handle.net/20.500.14038/35047PubMed ID
16617103Related Resources
Link to Article in PubMedRights
Publisher PDF posted as allowed by the publisher's author rights policy at http://www.pnas.org/site/aboutpnas/authorfaq.xhtml.ae974a485f413a2113503eed53cd6c53
10.1073/pnas.0601932103